TEAE: Clinical Safety Definition and CDISC Guide

Q: What is the difference between an AE and a TEAE?

An adverse event (AE) includes any untoward medical occurrence observed at any time during trial participation. A treatment-emergent adverse event (TEAE) is a temporal subset arising on or after the first dose, or a baseline condition that worsens after treatment begins.

Q: How is a TEAE flagged in CDISC ADaM datasets?

In ADaM ADAE, TRTEMFL is set to “Y” if the event start date/time (ASTDTM) falls between first treatment (TRTSDTM) and the post-treatment window end. Otherwise, it is set to “N”.

Q: Does a TEAE require a causal relationship to the study drug?

No. Classification as a TEAE depends entirely on timing relative to dosing. An event is classified as a TEAE even if considered unrelated to the study drug. Causality is evaluated as a separate variable.

Q: How are partial or missing AE start dates handled?

When an onset day is missing but the month and year match treatment initiation, the start date is imputed to the treatment start date so the event is conservatively classified as treatment-emergent.

Q: What is the standard post-treatment follow-up window for TEAEs?

The standard post-treatment window is typically 30 days following the final dose, or five elimination half-lives (5 × t₁/₂) of the drug, whichever is longer.

A Treatment-Emergent Adverse Event (TEAE) is any untoward medical occurrence in a clinical trial participant that begins after receiving study treatment, or a baseline condition that worsens during or after exposure. For trial sponsors, investigators, and data managers, TEAE tracking forms the foundation of safety evaluation under International Council for Harmonisation (ICH) and FDA guidelines. Properly classifying events separates on-study safety signals from conditions recorded on a medical history form and ensures that datasets submitted for a new drug application meet regulatory standards.

What it is and who runs it

As described on official FDA, ICH, and CDISC standards documentation on November 9, 2026, a Treatment-Emergent Adverse Event (TEAE) is defined under ICH E9 (Section 5.2.2) and NCI Thesaurus (Code C41331) as an adverse event that emerges during treatment having been absent pre-treatment, or worsens relative to the pre-treatment state.

Clinical safety standards and TEAE methodologies are governed by three primary bodies:

International Council for Harmonisation (ICH): Sets global guidelines, including ICH E2A for expedited safety definitions, ICH E3 for clinical study reports, and ICH E9 for statistical principles. For foundational rules, see ICH E2A clinical safety data management.
Regulatory Authorities (FDA, EMA, PMDA): Enforce clinical safety rules. The FDA mandates safety monitoring under 21 CFR 312.32 for IND applications and requires standardized summary tabulations in Module 5 of the eCTD.
Clinical Data Interchange Standards Consortium (CDISC): Maintains data standards mandated by regulators, specifically SDTM and ADaM datasets.

A core principle of TEAE reporting is that classification is purely temporal, not causal. Any adverse event occurring during the treatment window is logged as a TEAE regardless of suspected drug relationship. Causality is evaluated as a separate analytical attribute.

Eligibility

The applicability of TEAE tracking is defined by protocol safety populations and baseline screening standards, as described on official FDA and CDISC standards documentation on November 9, 2026. The primary population evaluated is the Safety Analysis Set, which ICH E9 defines as all randomized or enrolled participants who receive at least one dose of investigational product or comparator treatment. Subjects randomized but never dosed are excluded from TEAE summaries.

Establishing eligibility for TEAE classification requires two baseline benchmarks:

Pre-Treatment Baseline Documentation: Investigators must record all active conditions, chronic diagnoses, and baseline symptoms during screening in the CDISC SDTM Medical History (MH) domain or pre-treatment Adverse Events (AE) domain.
Comparator and Placebo Inclusivity: Identical TEAE capture criteria apply across experimental, active comparator, and placebo arms to support valid risk calculations.

What it funds or requires

Sponsors and CROs must satisfy specific regulatory and data standards when submitting TEAE data:

ICH E3 Clinical Study Report Displays

Under ICH E3 Section 12.2, sponsors submitting a CSR must present an orderly accounting of post-treatment adverse events:

Section 12.2.1: Brief summary of overall TEAE incidence, serious adverse events (SAEs), deaths, and discontinuations due to AEs.
Section 12.2.2: Display of TEAE incidence tables grouped by body system and term. Per the ICH E3 Q&A (R1), in-text tables focus on common events exceeding a threshold (such as ≥1% or ≥5%) without individual patient identifiers. Full tabulations belong in Section 14.3.1, and individual listings in Section 16.2.7.

MedDRA Coding and CDISC Standards

Verbatim terms must be mapped hierarchically to MedDRA Preferred Terms (PT) and System Organ Classes (SOC). In electronic datasets, TEAEs must be formatted in two CDISC tiers:

SDTM AE Domain: Captures raw event records (AESTDTC, AEENDTC, AESEV/AETOXGR, AEREL, and AETRTEM).
ADaM ADAE Dataset: Provides analysis-ready records with the derived variable TRTEMFL (Treatment-Emergent Analysis Flag: “Y” or “N”).

Serious events require expedited assessment under 21 CFR 312.32 and CIOMS guidelines and CIOMS I reporting. Failure to maintain compliant safety monitoring can trigger an FDA clinical hold.

Application or compliance steps

Operationalizing TEAE compliance involves six sequential steps:

Document Baseline Health: Record pre-existing conditions and baseline symptoms before first dose administration.
Capture On-Study Events: Record adverse events at each visit using non-directive questioning, noting timestamps and resolution.
Code and Grade Events: Map verbatim terms to MedDRA PTs and assign CTCAE severity grades (grades 1 to 5).
Derive TRTEMFL in ADaM ADAE: Compare analysis start date/time (ASTDTM) with treatment start (TRTSDTM) and treatment end (TRTEDTM):
- If ASTDTM ≥ TRTSDTM and ASTDTM ≤ TRTEDTM + Emergence Window, set TRTEMFL = "Y".
- If ASTDTM < TRTSDTM, set TRTEMFL = "N", unless a pre-existing condition increased in severity or CTCAE grade on or after TRTSDTM, in which case set TRTEMFL = "Y".
Apply Conservative Imputation for Partial Dates: If the event start day is missing but month and year match TRTSDT, impute the day to equal TRTSDT to conservatively flag the event as treatment-emergent.
Generate CSR Tables and Reconcile: Calculate subject incidence (counting each subject once per PT and SOC at maximum severity) and reconcile denominators against the ADSL safety set.

Typical timeline phases

TEAE monitoring follows four phases across a trial, as described on official FDA and CDISC standards documentation on November 9, 2026:

Screening and Baseline Phase: Spans from consent to the minute prior to first dose. Events establish baseline status and receive TRTEMFL = "N".
Active On-Treatment Phase: Extends from first dose timestamp through final dose administration. New or worsening events are classified as TEAEs.
Post-Treatment Emergence Window: Continues after the final dose for a specified duration—typically 30 days, or five elimination half-lives (5 × t₁/₂), whichever is longer. Events starting in this window receive TRTEMFL = "Y".
Long-Term Follow-Up: Extended surveillance for therapies with delayed risks (e.g., cell or gene therapies). Events occurring after the primary window are reported as late-onset events.

Common mistakes

Regulatory audits regularly identify several common mistakes in TEAE compliance:

Conflating Total Events with Subject Incidence: Reporting raw event counts rather than unique subjects affected. Multiple episodes of the same event in one participant count as an incidence of 1.
Ignoring Worsening of Baseline Conditions: Treating all baseline symptoms as non-emergent, even when they increase in CTCAE grade or frequency after dosing begins.
Inconsistent Window Definitions: Discrepancies between the emergence window defined in the SAP (e.g., 28 vs 30 days) and the derivation in ADaM ADAE.
Non-Conservative Date Imputation: Imputing missing start dates into pre-treatment periods, improperly excluding potential safety signals.
Mismatched Safety Denominators: Calculating TEAE percentage rates using the Intent-to-Treat (ITT) population instead of the Safety Analysis Set.

Related programs

Clinical safety frameworks differentiate TEAEs from related regulatory terms:

Classification	Standard	Core Definition	Causal?	Reporting Channel
TEAE	ICH E3 / E9	Untoward event emerging or worsening on or after first dose.	No	CSR Section 12.2 and DSUR summaries.
AE	ICH E2A	Any untoward medical occurrence in a clinical participant.	No	Logged in eCRF and SDTM AE domain.
ADR	ICH E2A	Untoward occurrence with a reasonable possibility of causal link.	Yes	Routine and expedited safety summaries; IB.
SAE	21 CFR 312.32	Event resulting in death, life threat, hospitalization, or disability.	No	Expedited to sponsor in 24 hours; CSR Section 12.3.1.
SUSAR	21 CFR 312.32	Serious, unexpected, and suspected drug-related event.	Yes	Expedited to FDA within 7 or 15 days under a SUSAR framework.
AESI	ICH E2F	Pre-identified medical concern requiring focused monitoring.	Protocol	Targeted safety tables in DSUR and CSR.

FAQ

What is the difference between an AE and a TEAE?